GlassScriptPhysician profile
Ryan L Westbroek
NPI 1144608050
$12,295.27
in general payments reported to CMS, 2019-2025
41 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,170 · 2022: $483 · 2023: $927 · 2024: $900 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $8,383.96 | 2021 | |
| Abbvie INC. | $1,572.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.85 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $312.80 | 2023-2025 | Sunosi, Symbravo, Auvelity |
| Novo Nordisk INC | $300.70 | 2023-2024 | Wegovy |
| Abbott Laboratories | $127.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Grt US Holding, INC. | $119.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.48 | 2021-2022 | |
| Lilly USA, LLC | $112.77 | 2021-2024 | Zepbound, Mounjaro |
| Alkermes, INC. | $81.35 | 2024 | Lybalvi |
| Amarin Pharma, INC. | $76.39 | 2021 | |
| Exeltis, USA INC. | $67.34 | 2025 | Slynd, Twirla |
| Antares Pharma, INC. | $57.21 | 2021-2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $47.32 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $47.17 | 2021-2025 | Veozah |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Westbroek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.